developer_as

About developer_as

This author has not yet filled in any details.
So far developer_as has created 24 blog entries.

Arix Bioscience participates in $67 million Series C financing for Amplyx Pharmaceuticals

Series C financing to fund Phase II clinical trials of APX001, a novel antifungal agent to treat life-threatening invasive infections LONDON, 2 August, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “Arix”), a global healthcare and life science company supporting medical innovation, today announces that it has acquired an interest in Amplyx Pharmaceuticals (“Amplyx”) [...]

2017-08-02T10:40:40+00:00 August 2nd, 2017|News Release|

Arix Bioscience Half Yearly Report for the Six Months Ended 30 June 2017

Transformative period with good progress across the business LONDON, 31 July 2017: Arix Bioscience plc (LSE:ARIX) ("Arix Bioscience", "Arix" or the "Company"), a global life sciences company supporting medical innovation, today announces its financial results for the six-month period ended 30 June 2017. Highlights Successful IPO on the Main Market of the London Stock Exchange in [...]

2017-07-31T10:07:03+00:00 July 31st, 2017|News Release|

Arix Bioscience co-leads $29 million Series A financing for PreciThera, Inc.

Funding to develop novel biologics targeting orphan bone diseases into clinical trials LONDON, 27 July 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “Arix”), a global healthcare and life science company supporting medical innovation, today announces that it has co-led an oversubscribed Series A financing round raising $29 million ($36 million CAD) for PreciThera, Inc. [...]

2017-07-27T09:48:14+00:00 July 27th, 2017|News Release|

Arix Bioscience appoints Meghan FitzGerald to Board of Directors

LONDON, 21 July 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience”, or the “Company”), a global healthcare and life science company supporting medical innovation, today announces the appointment of Meghan FitzGerald as a Non-Executive Director of the Company. The appointment is with immediate effect and she will be a member of the Board’s Audit Committee. [...]

2017-07-21T19:01:57+00:00 July 21st, 2017|News Release|

Arix Bioscience leads $45 million Series B financing round into LogicBio Therapeutics

Funding to advance gene therapies targeting orphan paediatric disorders through clinical trials LONDON, 28 June, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or the “Company”), a global healthcare and life science company supporting medical innovation, today announces that it has led an oversubscribed Series B financing round raising $45 million for LogicBio Therapeutics Inc. [...]

2017-06-28T11:58:57+00:00 June 28th, 2017|News Release|

Arix Bioscience participates in $20 million fundraise for Mitoconix Bio

Series A finance raised by high quality investor syndicate for neurodegenerative diseases therapies LONDON, 27 June, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or the “Company”), a global healthcare and life science company supporting medical innovation, today announces that it has acquired an interest in Mitoconix Bio Ltd. (“Mitoconix Bio”) as part of an [...]

2017-06-28T11:56:40+00:00 June 27th, 2017|News Release|

Arix Bioscience notes Artios Pharma’s new collaboration to develop inhibitors of novel cancer targets

LONDON, 12 June, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or the “Company”), a global healthcare and life science company supporting medical innovation, is pleased to note the announcement by Artios Pharma Ltd, an Arix Bioscience Group Business, that it has signed a research collaboration and option agreement with Masaryk University (“MU”) in the Czech [...]

2017-06-12T09:30:41+00:00 June 12th, 2017|News Release|

Arix Bioscience notes the formation of Artios Pharma’s world-leading Scientific Advisory Board

Dr Simon Boulton – Senior Group Leader at the Francis Crick Institute and VP of Scientific Strategy at Artios Dr KJ Patel – tenured Principal Investigator at the Medical Research Council Laboratory of Molecular Biology at the University of Cambridge Dr Jos Jonkers – Professor of Molecular Experimental Oncogenetics and Cancer Therapeutics, and Head of Molecular Pathology at [...]

2017-06-08T09:52:48+00:00 June 8th, 2017|News Release|

Arix Bioscience to present at Jefferies 2017 Global Healthcare Conference in New York

LONDON, 31 May, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces that Joe Anderson, Chief Executive Officer of Arix Bioscience, will present at the Jefferies 2017 Global Healthcare Conference to be held on 6-8 June in New York, US. The [...]

2017-05-31T22:52:10+00:00 May 31st, 2017|News Release|

Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics

- Funding to advance two of Harpoon’s immuno-oncology programmes into clinical trials - LONDON, 25 May, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announced that Harpoon Therapeutics, a new Arix Group Business, has closed a Series B investment round raising [...]

2017-05-25T10:41:32+00:00 May 25th, 2017|News Release|